Peptide Knowledge Base · Metabolic
Survodutide: what it is, what the evidence says, and its real status
An investigational GLP-1/glucagon dual agonist studied for both weight and liver disease (MASH).
Short version: a dual agonist whose differentiator is the liver, it is being studied in MASH as well as weight. Investigational; not approved, not available.
Can you actually get it?
Plain-English verdict: Waitlist / education.
Regulatory status: Investigational (Phase 3) · Not yet approved.
Not available to prescribe. Survodutide is an investigational GLP-1/glucagon dual agonist (Boehringer Ingelheim) in Phase-3 trials (SYNCHRONIZE). Not FDA-approved, not compoundable, education and demand-capture only.
How does Survodutide work?
A dual agonist at GLP-1 and glucagon receptors; the glucagon arm adds energy expenditure and a direct hepatic effect studied in liver disease.
What it does — and what it does not do
What it does: Studied for weight reduction and for improvement of MASH (metabolic-associated steatohepatitis).
What it does not do: It is not approved, not available, and not a liver treatment you can obtain; the MASH data is trial-stage.
How honest is the evidence?
Evidence grade B — Phase-2 MASH data; Phase-3 ongoing, re-verify. Read our grading methodology for what each grade means.
What we still don't know: Long-term outcomes and the MASH benefit are still being established in Phase-3.
WADA status: Not prohibited.
How it is taken
What the literature reports: subcutaneous, weekly, titrated. Educational only, no dose figures.
Who should not take it
Investigational, safety not fully characterized; clinician-gated.
Sources
Survodutide Phase-2 MASH (NEJM 2024) · SYNCHRONIZE Phase-3 (ongoing, re-verify)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.